New immune checkpoints in DLBCL include T cell immune receptors with Ig and ITIM domains (TIGIT), lymphocyte-activation-gene-3 (LAG-3), and TIM-3. The gene discussed is HAVCR2; the disease is diffuse large B-cell lymphoma.